Panbela Therapeutics Inc PBLA shares are trading higher by 9.7% to $0.50, though off the session high of $0.64. The move comes after the company announced FDA approval of eflornithine, a drug they divested to US WorldMeds, for treating high-risk neuroblastoma patients who responded partially to prior therapies.
Panbela Therapeutics says this marks the first FDA approval for a polyamine targeted therapy in cancer. Panbela stands to receive up to $9.5 million based on milestones achieved by USWM, emphasizing the significance of polyamines in cancer therapy.
Panbela's executives expressed excitement over the approval, highlighting its potential impact on neuroblastoma treatment and the broader implications for other cancers being explored.
See Also: Why Fresh Tracks Therapeutics (FRTX) Shares Are Volatile
According to data from Benzinga Pro, PBLA has a 52-week high of $225.71 and a 52-week low of $0.45.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
